Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Relvar Ellipta’s benefits unclear in COPD treatment

Relvar Ellipta

There is insufficient evidence to recommend Relvar Ellipta over existing inhaled corticosteroid and long-acting beta2 agonist combinations, says DTB

The benefit of Relvar Ellipta — a new dry powder combination inhaler used once a day as maintenance treatment for chronic obstructive pulmonary disease (COPD) — over twice-daily products is still unclear, according to the latest Drugs and Therapeutics Bulletin (DTB).

The inhaler, which contains fluticasone furoate and vilanterol trifenatate, improves lung function compared with placebo and its individual components. But when its benefits are compared with a combination of fluticasone and salmeterol, the results are not “statistically significant”, the DTB review says.

Compared with vilanterol alone, the combination inhaler achieves a small reduction in moderate to severe exacerbations but makes no difference in the incidence of serious exacerbations requiring hospital admission, says the DTB.

The review urges healthcare professionals to note concerns raised over the potential for confusion over the name and colour of the device and concludes that there “is insufficient evidence to recommend fluticasone/vilanterol over existing inhaled corticosteroid and long-acting beta2 agonist combinations”.

The review comes three months after Relvar Ellipta and its use in the treatment of asthma was the focus of a National Institute for Health and care Excellence evidence summary.

The DTB points out that the review was solely about the performance of Revlar Ellipta in treating COPD. It said that a future issue will review the product’s use in the management of asthma.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11139055

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.